NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

UTI sufferers have a new treatment option—and it's the first new class of antibiotics the FDA has approved for urinary tract ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.

Following Pfizer's disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock, will become Haleon's largest ...

The total sale represents 7.3% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

GSK PLC closed 15.77% below its 52-week high of £18.24, which the company reached on May 16th.